Have a personal or library account? Click to login
The Role of Three Plasma Proteins in the Diagnosis of Ovarian Tumors Cover

The Role of Three Plasma Proteins in the Diagnosis of Ovarian Tumors

Journal of Biomedical and Clinical Research
Volume 15 (2022): Issue 1 (June 2022)
By: Valeria Z. Racheva,  Adelaida L. Ruseva,  Svetlana A. Mateva and  Ivan Tsv. Malkodanski  
Open Access
|Jul 2022

References

  1. 1. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001;19(3):537–42.10.3892/ijo.19.3.537
    Search in Google ScholarBack to article
  2. 2. Cancer incidence in Bulgaria, 2014-2015. Bulgarian National Cancer Registry 2015. (full text: http://www.sbaloncology.bg/bg/bulgarian-cancer-registry.html)
    Search in Google ScholarBack to article
  3. 3. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer medicine. 2019 Nov;8(16):7018-31.10.1002/cam4.2560
    Search in Google ScholarBack to article
  4. 4. Rastogi M, Gupta S, Sachan M. Biomarkers towards ovarian cancer diagnostics: present and future prospects. Brazilian archives of biology and technology. 2016 Oct 31;59.10.1590/1678-4324-2016160070
    Search in Google ScholarBack to article
  5. 5. Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE et al. Diagnostic performance of CA 125, HE 4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of clinical laboratory analysis. 2019 Jan;33(1):e22624.10.1002/jcla.22624
    Search in Google ScholarBack to article
  6. 6. Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 2012 Jan;8(1):55-71.10.2217/fon.11.135
    Search in Google ScholarBack to article
  7. 7. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355-66.10.1074/mcp.R400006-MCP200
    Search in Google ScholarBack to article
  8. 8. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer. 2001;11(Suppl 1):3-610.1046/j.1525-1438.2001.11(suppl.1)sup1003.x
    Search in Google ScholarBack to article
  9. 9. Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One. 2012;7(9): e44960.10.1371/journal.pone.0044960343817522970327
    Search in Google ScholarBack to article
  10. 10. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004 Aug 15;64(16):5882-90.10.1158/0008-5472.CAN-04-074615313933
    Search in Google ScholarBack to article
  11. 11. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast Jr RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecologic oncology. 2011 Sep 1;122(3):548-53.10.1016/j.ygyno.2011.06.002315264621708402
    Search in Google ScholarBack to article
  12. 12. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast Jr RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic oncology. 2005 Nov 1;99(2):267-77.10.1016/j.ygyno.2005.06.040
    Search in Google ScholarBack to article
  13. 13. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O‘Briant K. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. Journal of the National Cancer Institute. 2010 Jan 6;102(1):26-38.10.1093/jnci/djp438
    Search in Google ScholarBack to article
  14. 14. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 2008 Jul 9;3(7):e2633.10.1371/journal.pone.0002633
    Search in Google ScholarBack to article
  15. 15. Mählck CG, Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest. 1994;37(2):135-40.10.1159/000292542
    Search in Google ScholarBack to article
  16. 16. Kuesel AC, Kroft T, Préfontaine M, Smith IC. Lipoprotein (a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. International journal of cancer. 1992 Sep 30;52(3):341-6.10.1002/ijc.2910520302
    Search in Google ScholarBack to article
  17. 17. Gadomska H, Grzechocińska B, Janecki J, Nowicka G, Powolny M, Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2005 May 1;120(1):87-90.10.1016/j.ejogrb.2004.02.045
    Search in Google ScholarBack to article
  18. 18. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC cancer. 2017 Dec;17(1):1-8.10.1186/s12885-017-3220-x
    Search in Google ScholarBack to article
  19. 19. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009 Oct 1;8(19):3107-11.10.4161/cc.8.19.9590
    Search in Google ScholarBack to article
  20. 20. 20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001 Feb 17;357(9255):539-45.10.1016/S0140-6736(00)04046-0
    Search in Google ScholarBack to article
  21. 21. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biology of reproduction. 1994 Feb 1;50(2):233-8.10.1095/biolreprod50.2.2338142541
    Search in Google ScholarBack to article
  22. 22. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia. Lancet. 1971 Jul 17;2(7716):163.10.1016/S0140-6736(71)92335-X
    Search in Google ScholarBack to article
  23. 23. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000 Mar 1;11(2):111-7.10.1097/00001648-200003000-00006
    Search in Google ScholarBack to article
  24. 24. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. American journal of obstetrics and gynecology. 2004 Sep 1;191(3):733-40.10.1016/j.ajog.2004.03.035
    Search in Google ScholarBack to article
  25. 25. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. International Journal of Cancer. 1997 Jun 11;71(6):948-51.10.1002/(SICI)1097-0215(19970611)71:6<948::AID-IJC6>3.0.CO;2-Y
    Search in Google ScholarBack to article
  26. 26. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research. 2011 Mar 1;4(3):365-7410.1158/1940-6207.CAPR-10-0195
    Search in Google ScholarBack to article
  27. 27. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 2004 Feb 10;44:239-67.10.1146/annurev.pharmtox.44.101802.121851
    Search in Google ScholarBack to article
  28. 28. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free radical biology and medicine. 1990 Jan 1;9(6):515-40.10.1016/0891-5849(90)90131-2
    Search in Google ScholarBack to article
  29. 29. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Human reproduction. 1989 Jan 1;4(1):1-2.10.1093/oxfordjournals.humrep.a136832
    Search in Google ScholarBack to article
  30. 30. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec;13(4):179-87. PMID: 10228898.10.1177/172460089801300402
    Search in Google ScholarBack to article
  31. 31. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecologic oncology. 2001 Jul 1;82(1):40-8.10.1006/gyno.2001.6253
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/jbcr-2022-0005 | Journal eISSN: 1313-9053
Journal RSS Feed
Language: English
Page range: 41 - 46
Submitted on: Dec 22, 2021
|
Accepted on: Jan 21, 2022
|
Published on: Jul 13, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
ovarian cancer,
transthyretin,
apoA1 lipoprotein,
CA 125,
diagnostic reliability
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Ophthalmology,
Public health,
Pharmacy,
Clinical pharmacy

© 2022 Valeria Z. Racheva, Adelaida L. Ruseva, Svetlana A. Mateva, Ivan Tsv. Malkodanski, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 15 (2022): Issue 1 (June 2022)Next article